home

Merck wins high-stakes battle with Gilead over hep C patents

EVENTSSTAT2016-03-23 10:44 Read   109

A federal jury on Tuesday upheld the validity of two Merck patents in a high-stakes battle with Gilead Sciences, which may now have to pay royalties on some of the billions of dollars in sales generated by its wildly successful hepatitis C treatments.

GSK's chief executive Sir Andrew Witty to retire next year

EVENTSGSK2016-03-21 14:45 Read   124

GlaxoSmithKline has confirmed that chief executive Sir Andrew Witty intends to retire next year, leaving a position he has held since 2008.

Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH)

EVENTSNovimmune2016-03-21 14:19 Read   136

Novimmune, a Swiss biotech company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH with refractory disease, or with recurrent or progressive disease during conventional therapy.

What's next for Gilead in oncology?

EVENTSGilead2016-03-21 14:01 Read   234

As competition for its hepatitis C drugs intensifies, Gilead Sciences ($GILD) has been working to build up in other therapeutic areas, especially cancer. And while a painful clinical failure for the blockbuster hopeful Zydelig and the high-profile departure of oncology head Philippe Bishop have hamstrung those efforts, Gilead is bullish about its future in the field.

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

EVENTSChi Med2016-03-18 14:56 Read   122

Hutchison China MediTech Limited (“Chi Med”) (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of approximately US$101.25 million.

Roche receives China Food and Drug Administration (CFDA) approval for the CINtec(R) PLUS Cytology test to help prevent women from developing cervical cancer

EVENTSRoche2016-03-13 07:28 Read   242

Roche announced the China Food and Drug Administration (CFDA) approval of the CINtec(R) PLUS Cytology test, designed to improve the detection and early intervention of pre-cancerous cervical disease.

Chinese immunotherapy biotech BeiGene sets terms for $127 million IPO

EVENTSNasdaq2016-01-22 09:33 Read   200

BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday.

Pfizer, Allergan agree on $150B-plus megamerger: WSJ

EVENTSWSJ2015-11-23 16:06 Read   313

The agreement's been made: The boards at Pfizer and Allergan have ratified a megamerger--worth more than $150 billion--that will create the world's biggest pharma company

Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress

EVENTSMerck2015-11-23 10:44 Read   631

Merck, today announced findings from three studies investigating the use of KEYTRUDA(pembrolizumab), the company’s anti-PD-1 therapy, in combination with three other immunotherapies – epacadostat, IMLYGICTM (talimogene laherparepvec), and ipilimumab – in patients with advanced melanoma.

BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies

EVENTSBioMarin2015-11-23 09:36 Read   488

BioMarin Pharmaceutical Inc. today announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized, placebo-controlled studies that were conducted contemporaneously.

AstraZeneca, Sanofi swap 210,000 compounds in no-cash deal

EVENTSAstraZeneca2015-11-22 22:01 Read   488

AstraZeneca and Sanofi have exchanged 210,000 compounds from their respective libraries in a no-cash, no-strings-attached deal.

Biogen and Samsung's Enbrel biosimilar wins EMA nod for EU approval

EVENTSBiogen,2015-11-21 21:49 Read   499

Enbrel is one of the world's best-selling drugs with nearly $9 billion in global sales last year shared by Pfizer ($PFE) in Europe and Amgen ($AMGN) in the U.S. But competition is hot on its heels in the guise of biosimilars. And in the newest attack, a copycat version of the anti-TNF med from Biogen ($BIIB) and Samsung has been recommended for approval in Europe.